Invention Grant
- Patent Title: Mutated anti-TNFα antibodies and methods of their use
- Patent Title (中): 突变的抗TNFα抗体及其使用方法
-
Application No.: US14206296Application Date: 2014-03-12
-
Publication No.: US08921526B2Publication Date: 2014-12-30
- Inventor: Chris M. Chumsae , Zehra Kaymakcalan
- Applicant: AbbVie Inc.
- Applicant Address: US IL North Chicago
- Assignee: AbbVie, Inc.
- Current Assignee: AbbVie, Inc.
- Current Assignee Address: US IL North Chicago
- Agency: McCarter & English, LLP
- Agent Maria Laccotripe Zacharakis; Marcie B. Clarke
- Main IPC: C07K16/00
- IPC: C07K16/00 ; C07K16/18 ; A61K39/395 ; C07K16/24

Abstract:
The present invention is directed to modified antibodies, including anti-TNFα antibodies, in which C-terminal amino acids of heavy chain sequences are modified from a native sequence of proline-glycine-lysine (“PGK”) to one that includes a proline positioned between the glycine and lysine, resulting in a C-terminal sequence of proline-glycine-proline-lycine (“PGPK”). The invention further provides methods of producing and using such antibodies.
Public/Granted literature
- US20140271626A1 MUTATED ANTI-TNFa ANTIBODIES AND METHODS OF THEIR USE Public/Granted day:2014-09-18
Information query